argenx to Present at Upcoming Investor Conferences
argenx (ARGX) announced that management will participate in two investor conferences in November, with fireside chats in Boston and London.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
argenx (ARGX) announced that management will participate in two investor conferences in November, with fireside chats in Boston and London.
The Guggenheim 3rd Annual Healthcare Innovation Conference chat is November 10 at 2:00 p.m. ET; the Jefferies London Global Healthcare Conference chat is November 17 at 8:30 a.m. GMT. Live webcasts will be accessible through the company’s investor website, with replays available for approximately 30 days.
AI-generated analysis. How Rhea-AI works. Not financial advice.
November 3, 2026
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that members of the management team will participate in the following investor conferences in November:
- Guggenheim 3rd Annual Healthcare Innovation Conference. Fireside chat on Tuesday, November 10 at 2:00 p.m. ET in Boston, MA.
- Jefferies London Global Healthcare Conference. Fireside chat on Tuesday, November 17 at 8:30 a.m. GMT in London, UK.
A live webcast of the presentations may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcasts will be available on the argenx website for approximately 30 days following the presentation.
About argenx
argenx is the immunology innovation company, focused on turning immunology breakthroughs into medicines for patients. The company seeks novel biology wherever it emerges, co-creating with academic researchers through its Immunology Innovation Program (IIP) and investing in promising science, to develop treatments for people living with underserved diseases. By advancing molecules with the potential to reach multiple diseases and patient populations, argenx is building a world-class portfolio. This approach produced the first approved antibody fragment targeting the neonatal Fc receptor (FcRn) and today powers a growing pipeline of early and late-stage programs across several therapeutic areas. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Contacts
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
